MRK•November 20, 2026 at 12:39 PM UTCPharmaceuticals, Biotechnology & Life Sciences

Merck's Keytruda Shows Survival Benefit in Stomach/Esophageal Cancers, Reinforcing Franchise but Not Altering Thesis

Read source article

What happened

Merck reported that its cancer immunotherapy Keytruda prolonged survival in patients with advanced stomach and esophageal cancers in a clinical trial, according to Reuters. This positive outcome adds to Keytruda's extensive clinical evidence base and may support additional regulatory approvals or label expansions in upper gastrointestinal cancers. The DeepValue master report already highlights Keytruda's dominant position, generating $31.68B in 2025 sales (49% of total), but also flags the looming patent and IRA pricing cliffs starting in 2028-2029. While this news reinforces the drug's near-term commercial strength, it does not address the company's strategic challenge of diversifying beyond Keytruda or the ongoing Gardasil weakness in China. The market is likely to view this as a marginal positive, but it will not change the fundamental WAIT thesis centered on the 2026 headwinds and post-Keytruda transition.

Implication

The positive survival data for Keytruda in stomach/esophageal cancers modestly strengthens its commercial moat and could support incremental sales in a competitive oncology market, but it does not solve Merck's core problem: an over-reliance on a single product facing a dated exclusivity cliff. The market's focus remains on whether Gardasil shipments to China resume, whether the approximately $2.5B FY2026 headwind stays contained, and whether new launches like Winrevair and Capvaxive scale quickly enough to offset erosion. With the stock trading at 16.2x trailing earnings and a limited margin of safety, the risk-reward is balanced; upside requires evidence of sustained non-Keytruda growth before 2028, while downside is protected by a strong balance sheet. We maintain our WAIT rating, with an attractive entry around $105 and trim level above $135, and we would not upgrade based solely on Keytruda's clinical strength unless accompanied by clear progress on the diversification front. Investors should monitor the upcoming catalysts, including the April 28, 2026 Keytruda-related PDUFA decision and quarterly updates on the China shipment and headwind guidance, for any signal that alters the thesis.

Thesis delta

The thesis is unchanged. This news does not alter the core bull/bear setup: Keytruda's clinical strength is already well-known and priced, while the key risks are structural (patent cliff, pricing, Gardasil-China). If anything, it modestly reinforces the near-term revenue durability of Keytruda but does not reduce the need for diversification.

Confidence

moderate